The State of Metabolic Health in America, 2026 Baseline Edition · James M. Knox · DOI: 10.5281/zenodo.22772957 · Last reviewed: October 2026

Glossary

The State of Metabolic Health in America, 2026 Baseline Edition

Definitions of key terms used in this report. Where a term has a standard clinical or regulatory definition, that definition is used. Where definitions vary by source, the definition used in this report is stated and the source is noted.

Cardio-kidney-metabolic (CKM) syndrome
A term introduced by the American Heart Association in 2023 to describe the interconnected pathophysiology of cardiovascular disease, chronic kidney disease, and metabolic conditions including obesity and type 2 diabetes.
Clinical outcome
A change in a patient's health status, such as HbA1c reduction, weight loss, or blood pressure control. Distinguished from utilization and cost outcomes in this report.
Employer-sponsored insurance (ESI)
Health insurance coverage provided through an employer, covering the employee and often dependents. The primary source of health coverage for working-age adults in the United States.
GLP-1 receptor agonist
A class of medications that mimic the glucagon-like peptide-1 hormone, used to treat type 2 diabetes and obesity. Examples include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).
Metabolic health
A state in which key metabolic markers — including blood glucose, blood pressure, triglycerides, HDL cholesterol, and waist circumference — are within normal ranges without the use of medication.
Metabolic syndrome
A cluster of conditions — elevated blood glucose, high blood pressure, excess abdominal fat, high triglycerides, and low HDL cholesterol — that occur together and increase the risk of cardiovascular disease and type 2 diabetes.
Prediabetes
A condition in which blood glucose levels are higher than normal but not yet high enough to be classified as type 2 diabetes. Defined by the CDC as a fasting glucose of 100–125 mg/dL or an HbA1c of 5.7–6.4%.
Utilization outcome
A change in the use of health care services, such as emergency department visits, hospitalizations, or prescription fills. Distinguished from clinical outcomes in this report.

How to cite this page

Knox, J. M. (2026). The State of Metabolic Health in America, 2026 Baseline Edition: Annual Policy Report. Zenodo. https://doi.org/10.5281/zenodo.22772957

© 2026 James M. Knox. Figures may be reproduced with attribution: Knox, J. M. (2026). The State of Metabolic Health in America, 2026 Baseline Edition: Annual Policy Report. Zenodo. https://doi.org/10.5281/zenodo.22772957 ISSN 3144-8178 (Online)